The International Breast Cancer Survivorship and Supportive Care Conference gathers healthcare professionals and patient advocates worldwide to share groundbreaking research in this exciting and rapidly expanding field.
We invite abstract submissions showcasing innovative research of the highest quality. Consider submitting for the chance to present your research with a multidisciplinary audience at our inaugural conference.
Please review the submission guidelines, topic categories, presentation information, and policies related to abstracts outlined here. Abstracts must be submitted online via the submission portal.
Abstract Authorship and Limitations
Please review these guidelines around authorship:
- Authors may be the primary author on a maximum of TWO (2) abstracts.
- Authors may be the presenting author on a maximum of TWO (2) abstracts.
- The Submitting Author is required to ensure that all co-authors are aware of the content of the abstract before submitting.
- The Presenting Author must attend in person to present. Virtual presentation options will not be available.
- All accepted abstracts must have at least ONE (1) registered co-author (usually the presenting author) who has paid the registration fees to attend the conference to be included in the scientific program.
Abstract Structure and Guidelines
Please ensure that your abstract submission adheres to the following structure and guidelines:
- Describe the abstract so that the Program Committee can evaluate its quality and completeness. Abstracts will be judged based on the data in the submitted abstract.
- Abstracts may be up to 2,000 characters (approximately 300-350 words), not including spaces, for the total of your title, body, and table. They should be organized into FOUR (4) sections: Background, Methods, Results, and Conclusions.
- Each abstract can contain up to THREE (3) images or tables but no illustrations or graphics.
- Do not use proprietary drug names in the title or body. If necessary, it may be included in parentheses directly after the generic name on first use in the body of the abstract.
- The title should objectively describe the study without referring to study results or conclusions. The editors reserve the right to edit conclusive titles.
- Trials-in-Progress are permitted. However, the acceptance of your abstract will be determined by the reviewers who will be evaluating your abstract in relation to other abstracts which include results.
- If your abstract has been published in another journal, please consider any embargos or limitations these publications may have. However, we encourage you to update the title and content to avoid copyright issues.
- Upon submission, the Submitting Author confirms that the abstract has been proofread and that all information is correct.
- Changes are not permitted after the submission deadline.
Abstract Evaluation
Abstracts will be evaluated based on four key criteria:
- Impact: Significance of the research in enhancing care.
- Innovation: Originality of the study.
- Approach: Design of the study, including sample size and rigour of the research.
- Presentation: Clarity, logic, and completeness of the data presented.
Presentation Types
Poster Sessions
Selected abstracts will be presented in a dedicated poster session. The poster will be displayed digitally. Specific time allocation will be given to the presenter to present their poster and answer the question.
Abstract Submission Categories
Authors must select one track and one sub-category that best fits the subject of their abstract. The Program Committee reserves the right to re-categorize an abstract.
Prevention and Management of Side Effects from Cancer and Treatment
Abstracts in this category should explore how the physical, emotional, social, spiritual, and financial aspects of survivorship are assessed and addressed to improve overall quality of life. Submissions may highlight innovative interventions, tools, or care approaches for managing late effects, treatment-related symptoms, sexual health, psychological well-being, and survivorship challenges faced by both patients and caregivers.
Care Coordination and Provision
Abstracts in this category should address strategies that enhance communication, continuity, and quality of care across the cancer survivorship continuum. Submissions may explore models of care, provider education, chronic condition management, survivorship care planning, and system-level approaches to identifying and addressing gaps in access, transitions, and long-term follow-up.
Digital Health and AI
This category welcomes abstracts showcasing new digital tools and AI-driven solutions that support personalized survivorship care and address unmet needs identified through assessment. Topics may include virtual care delivery, remote symptom monitoring, and emerging technologies that enhance access, engagement, and continuity for breast cancer survivors.
Health Promotion
This category invites abstracts that address evidence-based strategies to promote healthy behaviors and reduce long-term risk among breast cancer survivors. Submissions may focus on lifestyle interventions such as physical activity, nutrition, smoking cessation, and integrative therapies to support survivorship and prevent recurrence or comorbidities.
Recurrence and Secondary Malignancies
Abstracts in this category should focus on assessing and addressing the risk, detection, and management of breast cancer recurrence and secondary cancers. Submissions may include innovations in genetic risk assessment, surveillance strategies, prevention efforts, and treatments that reflect the evolving needs of survivors at risk for or experiencing recurrent disease.